PL357945A1 - Analogi nukleozydowe ze zmodyfikowaną karboksamidami zasadą bicykliczną - Google Patents

Analogi nukleozydowe ze zmodyfikowaną karboksamidami zasadą bicykliczną

Info

Publication number: PL357945A1
Authority: PL; Poland
Prior art keywords: nucleoside analogs; carboxamidine; monocyclic base; modified monocyclic; carboxamidine modified
Prior art date: 2000-02-15

Application number

PL01357945A

Other languages

English (en)

Other versions

PL200140B1 (pl

Inventor

Robert Tam

Kanda Ramasamy

Zhi Hong

Johnson Lau

Original Assignee

Icn Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-15

Filing date

2001-02-15

Publication date

2004-08-09

2001-02-15 Application filed by Icn Pharmaceuticals, Inc. filed Critical Icn Pharmaceuticals, Inc.

2004-08-09 Publication of PL357945A1 publication Critical patent/PL357945A1/pl

2008-12-31 Publication of PL200140B1 publication Critical patent/PL200140B1/pl

Links

125000002950 monocyclic group Chemical group 0.000 title 1
239000002777 nucleoside Substances 0.000 title 1
150000003833 nucleoside derivatives Chemical class 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 2
208000036142 Viral infection Diseases 0.000 abstract 2
230000009385 viral infection Effects 0.000 abstract 2
241000700721 Hepatitis B virus Species 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Virology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Tropical Medicine & Parasitology (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

PL357945A 2000-02-15 2001-02-15 Zastosowanie karboksyamidyny o wzorze 1 PL200140B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18267600P	2000-02-15	2000-02-15
US09/595,365 US6455508B1 (en)	2000-02-15	2000-10-05	Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides

Publications (2)

Publication Number	Publication Date
PL357945A1 true PL357945A1 (pl)	2004-08-09
PL200140B1 PL200140B1 (pl)	2008-12-31

Family

ID=26878297

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL357945A PL200140B1 (pl)	2000-02-15	2001-02-15	Zastosowanie karboksyamidyny o wzorze 1
PL01365239A PL365239A1 (pl)	2000-02-15	2001-02-15	Analogi nukleozydowe ze zmodyfikowaną karboksamidami zasadą bicykliczną

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL01365239A PL365239A1 (pl)	2000-02-15	2001-02-15	Analogi nukleozydowe ze zmodyfikowaną karboksamidami zasadą bicykliczną

Country Status (28)

Country	Link
US (1)	US6455508B1 (pl)
EP (3)	EP1257281B8 (pl)
JP (3)	JP4975930B2 (pl)
KR (2)	KR20030005190A (pl)
CN (2)	CN1268335C (pl)
AT (1)	ATE377422T1 (pl)
AU (2)	AU783142B2 (pl)
BR (2)	BR0108402A (pl)
CA (2)	CA2395854A1 (pl)
CY (1)	CY1107103T1 (pl)
CZ (2)	CZ302327B6 (pl)
DE (1)	DE60131250T8 (pl)
DK (1)	DK1257281T3 (pl)
ES (2)	ES2528429T3 (pl)
HR (2)	HRP20020583A2 (pl)
HU (2)	HU229480B1 (pl)
IL (3)	IL150555A0 (pl)
MX (2)	MXPA02007931A (pl)
NO (2)	NO329927B1 (pl)
NZ (2)	NZ521390A (pl)
PL (2)	PL200140B1 (pl)
PT (1)	PT1257281E (pl)
RS (1)	RS20090086A (pl)
RU (2)	RU2259831C2 (pl)
SI (2)	SI21077A (pl)
SK (2)	SK11572002A3 (pl)
WO (2)	WO2001060379A1 (pl)
YU (1)	YU61502A (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6831069B2 (en) *	1999-08-27	2004-12-14	Ribapharm Inc.	Pyrrolo[2,3-d]pyrimidine nucleoside analogs
US7638496B2 (en) *	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
US7056895B2 (en) *	2000-02-15	2006-06-06	Valeant Pharmaceuticals International	Tirazole nucleoside analogs and methods for using same
PY0111577A (es)	2000-05-23	2017-01-02	Idenix Cayman Ltd	Métodos y composiciones para el tratamiento del virus de la hepatitis c
BR0111196A (pt) *	2000-05-26	2004-04-06	Idenix Cayman Ltd	Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
IL156641A0 (en)	2001-01-22	2004-01-04	Merck & Co Inc	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
WO2003037908A1 (en) *	2001-10-31	2003-05-08	Ribapharm Inc.	Antiviral combination therapy and compositions
AP2005003213A0 (en)	2002-06-28	2005-03-31	Univ Cagliari	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections.
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN101172993A (zh)	2002-06-28	2008-05-07	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
RU2005118421A (ru)	2002-11-15	2006-01-20	Айденикс (Кайман) Лимитед (Ky)	2'-разветвленные нуклеозиды и мутация flaviviridae
AU2003300901A1 (en)	2002-12-12	2004-06-30	Idenix (Cayman) Limited	Process for the production of 2'-branched nucleosides
JP2006524227A (ja) *	2003-03-28	2006-10-26	ファーマセット，インク．	フラビウイルス科ウイルス感染の治療のための化合物
US20040197292A1 (en) *	2003-04-04	2004-10-07	The Procter & Gamble Company	Personal care composition containing an antidandruff component and a nonionic surfactant
US20040197287A1 (en) *	2003-04-04	2004-10-07	The Procter & Gamble Company	Personal care composition containing an antidandruff component and a nonionic surfactant
US20040202636A1 (en) *	2003-04-11	2004-10-14	Kaczvinsky Joseph Robert	Personal care composition containing an antidandruff component and a nonionic surfactant
US6930093B2 (en) *	2003-07-10	2005-08-16	Valeant Research & Development	Use of ribofuranose derivatives against inflammatory bowel diseases
US20050009848A1 (en) *	2003-07-10	2005-01-13	Icn Pharmaceuticals Switzerland Ltd.	Use of antivirals against inflammatory bowel diseases
WO2005018330A1 (en) *	2003-08-18	2005-03-03	Pharmasset, Inc.	Dosing regimen for flaviviridae therapy
US20050095218A1 (en) *	2003-10-29	2005-05-05	The Procter & Gamble Company	Personal care composition containing a detersive surfactant, an antidandruff component, and ketoamide surfactants
US20050182252A1 (en)	2004-02-13	2005-08-18	Reddy K. R.	Novel 2'-C-methyl nucleoside derivatives
AU2005254057B2 (en)	2004-06-15	2011-02-17	Isis Pharmaceuticals, Inc.	C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
JP4516863B2 (ja) *	2005-03-11	2010-08-04	株式会社ケンウッド	音声合成装置、音声合成方法及びプログラム
AU2006242475B2 (en)	2005-05-02	2011-07-07	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
US7470664B2 (en)	2005-07-20	2008-12-30	Merck & Co., Inc.	HCV NS3 protease inhibitors
AU2006275605B2 (en)	2005-08-01	2011-01-06	Merck Sharp & Dohme Corp.	Macrocyclic peptides as HCV NS3 protease inhibitors
US7781576B2 (en)	2005-12-23	2010-08-24	Idenix Pharmaceuticals, Inc.	Process for preparing a synthetic intermediate for preparation of branched nucleosides
AU2006342447B2 (en) *	2005-12-28	2013-06-20	Translational Therapeutics, Inc	Translational dysfunction based therapeutics
US8497292B2 (en)	2005-12-28	2013-07-30	Translational Therapeutics, Inc.	Translational dysfunction based therapeutics
GB0609492D0 (en)	2006-05-15	2006-06-21	Angeletti P Ist Richerche Bio	Therapeutic agents
GB0612423D0 (en)	2006-06-23	2006-08-02	Angeletti P Ist Richerche Bio	Therapeutic agents
WO2008005542A2 (en) *	2006-07-07	2008-01-10	Gilead Sciences, Inc.,	Antiviral phosphinate compounds
JP2010507656A (ja)	2006-10-24	2010-03-11	メルクエンドカムパニーインコーポレーテッド	Ｈｃｖｎｓ３プロテアーゼ阻害剤
EP2079479B1 (en)	2006-10-24	2014-11-26	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
US8309540B2 (en)	2006-10-24	2012-11-13	Merck Sharp & Dohme Corp.	HCV NS3 protease inhibitors
EP2086982B1 (en)	2006-10-27	2018-08-29	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
ES2444575T3 (es)	2006-10-27	2014-02-25	Merck Sharp & Dohme Corp.	Inhibidores de la proteasa NS3 del VHC
CA2672250C (en)	2006-12-20	2013-04-30	Ian Stansfield	Antiviral indoles
GB0625345D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
GB0625349D0 (en)	2006-12-20	2007-01-31	Angeletti P Ist Richerche Bio	Therapeutic compounds
WO2009010785A1 (en)	2007-07-17	2009-01-22	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa	Macrocyclic indole derivatives for the treatment of hepatitis c infections
AU2008277377B2 (en)	2007-07-19	2013-08-01	Msd Italia S.R.L.	Macrocyclic compounds as antiviral agents
EP2271345B1 (en)	2008-04-28	2015-05-20	Merck Sharp & Dohme Corp.	Hcv ns3 protease inhibitors
BRPI0916235B8 (pt)	2008-07-22	2021-05-25	Merck Sharp & Dohme	composto, composição farmacêutica, e, uso do composto ou da composição
WO2010082050A1 (en)	2009-01-16	2010-07-22	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en)	2009-01-20	2009-03-04	Angeletti P Ist Richerche Bio	Antiviral agents
EP2459582B1 (en)	2009-07-30	2015-05-27	Merck Sharp & Dohme Corp.	Hepatitis c virus ns3 protease inhibitors
US9328138B2 (en)	2011-11-15	2016-05-03	Msd Italia S.R.L.	HCV NS3 protease inhibitors
US20140356325A1 (en)	2012-01-12	2014-12-04	Ligand Pharmaceuticals Incorporated	Novel 2'-c-methyl nucleoside derivative compounds
CN102978264B (zh) *	2012-11-14	2014-12-10	广东肇庆星湖生物科技股份有限公司	一种他立韦林的制备方法
WO2014121417A1 (en)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en)	2013-02-07	2014-08-14	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
AU2015217221A1 (en)	2014-02-13	2016-08-11	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
WO2016003812A1 (en)	2014-07-02	2016-01-07	Ligand Pharmaceuticals, Inc.	Prodrug compounds and uses therof
EA201890454A1 (ru)	2015-08-06	2018-07-31	Чимерикс, Инк.	Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
US11111264B2 (en)	2017-09-21	2021-09-07	Chimerix, Inc.	Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
AU2019207625A1 (en)	2018-01-09	2020-07-30	Ligand Pharmaceuticals, Inc.	Acetal compounds and therapeutic uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE29835E (en)	1971-06-01	1978-11-14	Icn Pharmaceuticals	1,2,4-Triazole nucleosides
US3991078A (en)	1971-06-01	1976-11-09	Icn Pharmaceuticals, Inc.	N-substituted 1,2,4-triazoles
US3798209A (en)	1971-06-01	1974-03-19	Icn Pharmaceuticals	1,2,4-triazole nucleosides
US3984396A (en)	1971-06-01	1976-10-05	Icn Pharmaceuticals, Inc.	1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3962211A (en) *	1975-01-13	1976-06-08	The University Of Utah	7-substituted nucleoside compounds
US4093624A (en)	1977-01-31	1978-06-06	Icn Pharmaceuticals, Inc.	1,2,4-Thiadiazolidine-3,5-dione
SU1124559A1 (ru) *	1983-06-08	1986-07-07	Институт молекулярной биологии АН СССР	1-(2-Оксиэтоксиметил)-1,2,4-триазол-5-карбоксамид,обладающий активностью противвируса герпеса
JPS6426593A (en)	1987-07-21	1989-01-27	Asahi Glass Co Ltd	Nucleoside derivative
US4892865A (en) *	1987-12-01	1990-01-09	The Regents Of The University Of Michigan	Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US5405837A (en) *	1993-05-18	1995-04-11	Indiana University Foundation	Method for the treatment of neoplastic disease utilizing tiazofurin and ribavirin
SK283342B6 (sk) *	1996-01-23	2003-06-03	Icn Pharmaceuticals	Použitie ribavirínu na prípravu farmaceutického prostriedku
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
EP1027359B9 (en) *	1996-10-16	2003-09-17	Ribapharm, Inc.	Monocyclic l-nucleosides, analogs and uses thereof
BR0013642A (pt) *	1999-08-27	2002-05-07	Icn Pharmaceuticals	Análogos de nucleosìdeo de pirrolo[2,3-d]pirimidina

2000
- 2000-10-05 US US09/595,365 patent/US6455508B1/en not_active Expired - Lifetime
2001
- 2001-02-15 AU AU47988/01A patent/AU783142B2/en not_active Ceased
- 2001-02-15 DK DK01920996T patent/DK1257281T3/da active
- 2001-02-15 ES ES07107588.1T patent/ES2528429T3/es not_active Expired - Lifetime
- 2001-02-15 CA CA002395854A patent/CA2395854A1/en not_active Abandoned
- 2001-02-15 JP JP2001559475A patent/JP4975930B2/ja not_active Expired - Fee Related
- 2001-02-15 NZ NZ521390A patent/NZ521390A/en unknown
- 2001-02-15 EP EP01920996A patent/EP1257281B8/en not_active Expired - Lifetime
- 2001-02-15 SK SK1157-2002A patent/SK11572002A3/sk unknown
- 2001-02-15 AU AU38450/01A patent/AU3845001A/en not_active Abandoned
- 2001-02-15 JP JP2001559477A patent/JP2004510691A/ja active Pending
- 2001-02-15 HR HR20020583A patent/HRP20020583A2/xx not_active Application Discontinuation
- 2001-02-15 YU YU61502A patent/YU61502A/sh unknown
- 2001-02-15 PT PT01920996T patent/PT1257281E/pt unknown
- 2001-02-15 BR BR0108402-0A patent/BR0108402A/pt not_active Application Discontinuation
- 2001-02-15 HU HU0300027A patent/HU229480B1/hu unknown
- 2001-02-15 EP EP01910892A patent/EP1278528A4/en not_active Withdrawn
- 2001-02-15 SI SI200120011A patent/SI21077A/sl not_active IP Right Cessation
- 2001-02-15 SK SK1149-2002A patent/SK287765B6/sk not_active IP Right Cessation
- 2001-02-15 AT AT01920996T patent/ATE377422T1/de active
- 2001-02-15 WO PCT/US2001/040148 patent/WO2001060379A1/en not_active Ceased
- 2001-02-15 DE DE60131250T patent/DE60131250T8/de active Active
- 2001-02-15 KR KR1020027010593A patent/KR20030005190A/ko not_active Withdrawn
- 2001-02-15 CZ CZ20022798A patent/CZ302327B6/cs not_active IP Right Cessation
- 2001-02-15 ES ES01920996T patent/ES2295148T3/es not_active Expired - Lifetime
- 2001-02-15 RU RU2002120922/15A patent/RU2259831C2/ru active
- 2001-02-15 IL IL15055501A patent/IL150555A0/xx unknown
- 2001-02-15 IL IL15099001A patent/IL150990A0/xx unknown
- 2001-02-15 SI SI200120010A patent/SI21076A/sl not_active IP Right Cessation
- 2001-02-15 MX MXPA02007931A patent/MXPA02007931A/es active IP Right Grant
- 2001-02-15 CA CA2399208A patent/CA2399208C/en not_active Expired - Fee Related
- 2001-02-15 CN CNB018077455A patent/CN1268335C/zh not_active Expired - Fee Related
- 2001-02-15 EP EP07107588.1A patent/EP1813278B9/en not_active Expired - Lifetime
- 2001-02-15 HU HU0300912A patent/HUP0300912A2/hu unknown
- 2001-02-15 PL PL357945A patent/PL200140B1/pl unknown
- 2001-02-15 RS RSP-2009/0086A patent/RS20090086A/sr unknown
- 2001-02-15 HR HR20020657A patent/HRP20020657A2/hr not_active Application Discontinuation
- 2001-02-15 BR BR0108401-1A patent/BR0108401A/pt not_active IP Right Cessation
- 2001-02-15 NZ NZ52087701A patent/NZ520877A/xx not_active IP Right Cessation
- 2001-02-15 CZ CZ20022799A patent/CZ20022799A3/cs unknown
- 2001-02-15 CN CN01805036A patent/CN1420779A/zh active Pending
- 2001-02-15 MX MXPA02007932A patent/MXPA02007932A/es unknown
- 2001-02-15 RU RU2002120483/14A patent/RU2002120483A/ru not_active Application Discontinuation
- 2001-02-15 PL PL01365239A patent/PL365239A1/pl unknown
- 2001-02-15 KR KR1020027010417A patent/KR100811927B1/ko not_active Expired - Fee Related
- 2001-02-15 WO PCT/US2001/005172 patent/WO2001060381A1/en not_active Ceased
2002
- 2002-07-30 IL IL150990A patent/IL150990A/en not_active IP Right Cessation
- 2002-08-14 NO NO20023855A patent/NO329927B1/no not_active IP Right Cessation
- 2002-08-14 NO NO20023852A patent/NO20023852L/no not_active Application Discontinuation
2007
- 2007-12-19 CY CY20071101614T patent/CY1107103T1/el unknown
2009
- 2009-01-29 JP JP2009018382A patent/JP5253204B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1257281A1 (en)	2002-11-20
DE60131250T2 (de)	2008-08-28
EP1813278B9 (en)	2015-04-01
JP2004509061A (ja)	2004-03-25
SK287765B6 (sk)	2011-09-05
NZ521390A (en)	2004-05-28
SI21077A (sl)	2003-06-30
HRP20020583A2 (en)	2005-10-31
EP1257281B1 (en)	2007-11-07
EP1257281A4 (en)	2003-03-19
CZ20022798A3 (cs)	2003-03-12
JP2009102406A (ja)	2009-05-14
ES2528429T3 (es)	2015-02-09
NO20023852D0 (no)	2002-08-14
CA2399208C (en)	2010-04-13
EP1813278B1 (en)	2014-10-29
PT1257281E (pt)	2007-12-11
CA2399208A1 (en)	2001-08-23
CN1420779A (zh)	2003-05-28
IL150990A (en)	2009-05-04
MXPA02007932A (es)	2004-10-15
CN1438891A (zh)	2003-08-27
KR20030032917A (ko)	2003-04-26
PL200140B1 (pl)	2008-12-31
NO329927B1 (no)	2011-01-24
EP1278528A4 (en)	2003-03-19
JP2004510691A (ja)	2004-04-08
EP1278528A1 (en)	2003-01-29
WO2001060379A1 (en)	2001-08-23
HU229480B1 (en)	2014-01-28
DE60131250T8 (de)	2009-01-15
RU2259831C2 (ru)	2005-09-10
WO2001060381A1 (en)	2001-08-23
CZ302327B6 (cs)	2011-03-16
CA2395854A1 (en)	2001-08-23
KR100811927B1 (ko)	2008-03-10
IL150555A0 (en)	2003-02-12
JP5253204B2 (ja)	2013-07-31
HUP0300912A2 (hu)	2003-08-28
SI21076A (sl)	2003-06-30
AU3845001A (en)	2001-08-27
ES2528429T9 (es)	2015-05-07
EP1257281B8 (en)	2008-01-23
US6455508B1 (en)	2002-09-24
YU61502A (sh)	2006-03-03
SK11572002A3 (sk)	2003-02-04
DE60131250D1 (de)	2007-12-20
BR0108402A (pt)	2003-03-11
DK1257281T3 (da)	2008-01-14
BR0108401A (pt)	2004-01-06
IL150990A0 (en)	2003-02-12
EP1813278A1 (en)	2007-08-01
NO20023855L (no)	2002-10-08
JP4975930B2 (ja)	2012-07-11
SK11492002A3 (sk)	2003-02-04
KR20030005190A (ko)	2003-01-17
WO2001060381B1 (en)	2001-11-01
NZ520877A (en)	2004-12-24
ATE377422T1 (de)	2007-11-15
HUP0300027A3 (en)	2003-09-29
RS20090086A (sr)	2010-06-30
CZ20022799A3 (cs)	2003-09-17
RU2002120922A (ru)	2004-01-27
AU4798801A (en)	2001-08-27
CN1268335C (zh)	2006-08-09
NO20023855D0 (no)	2002-08-14
HK1051149A1 (en)	2003-07-25
RU2002120483A (ru)	2004-01-27
CY1107103T1 (el)	2012-10-24
HRP20020657A2 (en)	2005-10-31
ES2295148T3 (es)	2008-04-16
HUP0300027A2 (en)	2003-05-28
MXPA02007931A (es)	2004-10-15
NO20023852L (no)	2002-10-09
PL365239A1 (pl)	2004-12-27
AU783142B2 (en)	2005-09-29

Publication	Publication Date	Title
IL150990A0 (en)	2003-02-12	Nucleoside analogs with carboxamidine modified monocyclic base
MY128463A (en)	2007-02-28	4' substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
BG108439A (en)	2005-03-31	4'-substituted nucleosides
WO2003051306A3 (en)	2003-12-18	N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
AP1771A (en)	2007-08-23	3'-Prodrugs of 2'-deoxy-?-L-nucleosides.
EE02995B1 (et)	1997-06-16	1,3-oksatiolaannukleosiidi analoogide kasutamine hepatiit B ravimpreparaatide valmistamiseks
IL152934A (en)	2010-12-30	Use of a nucleoside in the manufacture of a medicament for treating heapatitis c virus
NZ609146A (en)	2014-08-29	Modified 4’-nucleosides as antiviral agents
NZ610715A (en)	2014-07-25	Antiviral compounds and methods
JP2004509061A5 (pl)	2006-01-05
WO2002032414A3 (en)	2003-04-03	Ribavirin-pegylated interferon alfa hcv combination therapy
JO2403B1 (en)	2007-06-17	Nickeloside derivatives antiviral
WO2000018417A3 (en)	2000-07-06	Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine
MX9202634A (es)	1994-01-31	Uso de analogos de nucleosido de 1,3-oxatiolano en el tratamiento de hepatitis b.